QT Imaging Holdings, Inc. (QTI) generates news tied to medical device commercialization, breast imaging technology and public company reporting. The company describes itself as focused on breast health management through radiation-free imaging technology, with the Breast Acoustic CT Scanner as its main named system.
QTI news often centers on the progress of its Breast Acoustic CT platform. Relevant company updates include scanner commercialization, distribution and direct commercial activity, development work on reconstruction and quantitative imaging algorithms, clinical workflow, the QTI Precision Pathway cloud platform and collaboration related to a multimodality viewer and quantitative analysis.
Regulatory and quality-related announcements are also important for this issuer because the company operates in a medical device category. QT Imaging has announced FDA clearance for its scanner as an adjunctive breast imaging device for adult women, Israeli Ministry of Health registration for commercialization in Israel and completion of an FDA routine inspection with zero Form 483 observations.
Financial and governance news adds another layer for QTI. The company's releases and filings include quarterly financial results, financing activity, shareholder letters, annual meeting results, executive appointments and equity incentive plan matters. Regular review of QTI news helps connect the company's breast imaging technology claims with commercialization updates, regulatory disclosures and public company governance events.
QT Imaging (Nasdaq: QTI) appointed leading breast surgical oncologist Dr. Barry Roseman as Senior Medical Advisor.
He will implement QT Imaging’s radiation-free, 3D breast imaging technology in a high-volume diagnostic and screening center, supporting physician training, workflow integration, patient access, and real-world data collection.
QT Imaging (Nasdaq: QTI) will report financial results for the quarter ended March 31, 2026 after market close on Wednesday, May 13, 2026, and will host an investor conference call the same day at 4:30 p.m. ET / 1:30 p.m. PT.
Participants may pre-register to receive a passcode and PIN; dial-in numbers are provided for U.S. and international callers. A live and archived webcast will be available on the company investor relations calendar.
QT Imaging (Nasdaq: QTI) launched the QT Imaging-Olea Viewer, a unified, multimodality breast imaging viewer developed with Olea Medical. The viewer integrates QTscan data with mammography, DBT, MRI, and ultrasound, supports 3D rendering and future AI/ML tools, and aims to streamline workflow and longitudinal patient review.
The product will be demonstrated at the SBI Breast Imaging Symposium, April 16-19, 2026 in Seattle; the collaboration began in January 2026.
QT Imaging (Nasdaq: QTI) CEO Dr. Raluca Dinu spoke at the inaugural Shiftmakers Gala at Harvard on March 27, 2026, emphasizing early breast cancer detection and the limits of mammography for women with dense breast tissue.
The company said its radiation-free imaging advances will be featured in The Shift to broaden awareness and reach more women and clinicians.
QT Imaging (Nasdaq: QTI) released image reconstruction software version 4.5.0 on April 1, 2026, improving spatial resolution and performance for challenging breast imaging cases.
Enhancements include spatially varying deconvolution, fusion of speed of sound and reflection data, better small-breast reconstruction, and improved assessment with implants.
QT Imaging (Nasdaq: QTI) reported 2025 revenue of $18.9 million, a record aided by shipping 40 scanners and exceeding guidance. The company affirmed 2026 revenue guidance of ~$39 million, citing contracted MOQs and initial QTI Cloud Platform revenue.
Key developments include AMA Category III CPT code approval (effective Jan 1, 2027), FDA 510(k) clearance for an updated scanner configuration, Nasdaq relisting, an $18.2 million private placement, and distribution agreements guaranteeing minimum orders in the UAE totaling 43 scanners (>$24 million revenue).
QT Imaging (Nasdaq: QTI) received UAE Emirates Drug Establishment clearance for its Breast Acoustic CT scanner, allowing importation, distribution, and marketing to licensed UAE healthcare facilities.
QT Imaging signed an exclusive UAE distribution deal with Al Naghi Medical and reported a $24 million revenue pipeline through 2028, expanding its commercial presence in the Middle East.
QT Imaging (Nasdaq: QTI) will report results for the three and 12 months ended December 31, 2025 and hold a conference call on March 25, 2026 at 4:30 p.m. ET (1:30 p.m. PT).
Pre-registration is available for immediate access; dial-in numbers are provided for U.S. and international participants. A live and archived webcast will be available on the company investor relations calendar.
QT Imaging (Nasdaq: QTI) received FDA 510(k) clearance on March 10, 2026 for an enhanced configuration of its Breast Acoustic CT scanner that improves visualization and expands coverage of posterior breast tissue.
The update uses a tilted transmitter geometry to better image breast tissue near the chest wall and continues to generate 3D tomographic images with quantified fibroglandular tissue volume (FGV) and FGV-to-total-breast-volume metrics.
QT Imaging (Nasdaq: QTI) appointed Dr. Mary W. Yamashita as Medical Advisor effective March 4, 2026. Dr. Yamashita will advise on clinical interpretation standards, structured reporting, training, and reader study design to support clinical integration of QT Imaging’s radiation-free 3D breast imaging technology.
She is Section Chief of Breast Imaging at USC Keck School of Medicine and Medical Director of mammography at two USC breast centers; her experience includes multicenter trials, research, and resident/fellow mentorship.